Comparison of combined, biochemical and nuchal translucency screening for Down syndrome in first trimester in Northern Finland

Acta Obstetricia et Gynecologica Scandinavica

Volumn 92, Issue 7, 2013, Pages 769-774

  Peuhkurinen, Sini ^a   Laitinen, Paivi ^b   Honkasalo, Timppa ^a   Ryynanen, Markku ^a   Marttala, Jaana ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Biochemical screening; combined screening; Down syndrome; first trimester; nuchal translucency; singleton pregnancy

Indexed keywords

CHORIONIC GONADOTROPIN; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; ARTICLE; DOWN SYNDROME; FALSE POSITIVE RESULT; FEMALE; FINLAND; FIRST TRIMESTER PREGNANCY; FLUOROIMMUNOASSAY; HUMAN; MAJOR CLINICAL STUDY; NUCHAL TRANSLUCENCY MEASUREMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBLIC HEALTH SERVICE;

ADULT; BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DOWN SYNDROME; FALSE POSITIVE REACTIONS; FEMALE; FINLAND; HUMANS; MATERNAL SERUM SCREENING TESTS; NUCHAL TRANSLUCENCY MEASUREMENT; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 84879205164     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1111/aogs.12095     Document Type: Article

References (27)

1. Benacerraf BR, Barss VA, Laboda LA,. A sonographic sign for the detection in the second trimester of the fetus with Down's syndrome. Am J Obstet Gynecol. 1985; 151: 1078-9.
2. Szabo J, Gellen J,. Nuchal fluid accumulation in trisomy-21 detected by vaginosonography in first trimester. Lancet. 1990; 336 (8723): 1133.
3. Ville Y, Lalondrelle C, Doumerc S, Daffos F, Frydman R, Oury JF, et al. First-trimester diagnosis of nuchal anomalies: significance and fetal outcome. Ultrasound Obstet Gynecol. 1992; 2: 314-16.
4. Nicolaides KH, Azar G, Byrne D, Mansur C, Marks K,. Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. BMJ. 1992; 304: 867-9.
5. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH,. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. fetal medicine foundation first trimester screening group. Lancet. 1998; 352: 343-6.
6. Theodoropoulos P, Lolis D, Papageorgiou C, Papaioannou S, Plachouras N, Makrydimas G,. Evaluation of first-trimester screening by fetal nuchal translucency and maternal age. Prenat Diagn. 1998; 18: 133-7.
7. Schwarzler P, Carvalho JS, Senat MV, Masroor T, Campbell S, Ville Y,. Screening for fetal aneuploidies and fetal cardiac abnormalities by nuchal translucency thickness measurement at 10-14 weeks of gestation as part of routine antenatal care in an unselected population. Br J Obstet Gynaecol. 1999; 106: 1029-34.
8. Souka AP, Snijders RJ, Novakov A, Soares W, Nicolaides KH,. Defects and syndromes in chromosomally normal fetuses with increased nuchal translucency thickness at 10-14 weeks of gestation. Ultrasound Obstet Gynecol. 1998; 11: 391-400.
9. Souka AP, Von Kaisenberg CS, Hyett JA, Sonek JD, Nicolaides KH,. Increased nuchal translucency with normal karyotype. Am J Obstet Gynecol. 2005; 192: 1005-21.
10. Braithwaite JM, Morris RW, Economides DL,. Nuchal translucency measurements: frequency distribution and changes with gestation in a general population. Br J Obstet Gynaecol. 1996; 103: 1201-4.
11. Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, et al. First- and Second-Trimester Evaluation of Risk (FASTER) Research Consortium. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med. 2005; 353: 2001-11.
12. Zoppi MA, Ibba RM, Floris M, Monni G,. Fetal nuchal translucency screening in 12495 pregnancies in Sardinia. Ultrasound Obstet Gynecol. 2001; 18: 649-51.
13. Kagan KO, Etchegaray A, Zhou Y, Wright D, Nicolaides KH,. Prospective validation of first-trimester combined screening for trisomy 21. Ultrasound Obstet Gynecol. 2009; 34: 14-18.
14. Ranta JK, Marttala J, Laitinen P, Kultti J, Kauhanen O, Romppanen J, et al. First trimester biochemistry at different maternal ages. Clin Chem Lab Med. 2011; 50: 549-55. (Epub ahead of print 24 November).
15. Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH,. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience. BJOG. 2003; 110: 281-6.
16. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM,. First and second trimester antenatal screening for Down's syndrome: the results of the serum, urine and ultrasound screening study (SURUSS). J Med Screen. 2003; 10: 56-104.
17. Tsukerman GL, Gusina NB, Cuckle HS,. Maternal serum screening for Down syndrome in the first trimester: experience from Belarus. Prenat Diagn. 1999; 19: 499-504.
18. Reynolds TM, Penney MD,. The mathematical basis of multivariate risk screening: with special reference to screening for Down's syndrome associated pregnancy. Ann Clin Biochem. 1990; 27: 452-8.
19. Cuckle HS, van Lith JM,. Appropriate biochemical parameters in first-trimester screening for Down syndrome. Prenat Diagn. 1999; 19: 505-12.
20. Wald NJ, Hackshaw AK,. Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome. Prenat Diagn. 1997; 17: 821-9.
21. Alexioy E, Alexioy E, Trakakis E, Kassanos D, Farmakidis G, Kondylios A, et al. Predictive value of increased nuchal translucency as a screening test for the detection of fetal chromosomal abnormalities. J Matern Fetal Neonatal Med. 2009; 22: 857-62.
22. Taipale P, Hiilesmaa V, Salonen R, Ylostalo P,. Increased nuchal translucency as a marker for fetal chromosomal defects. N Engl J Med. 1997; 337: 1654-8.
23. Spencer K, Crossley JA, Aitken DA, Nix AB, Dunstan FD, Williams K,. Temporal changes in maternal serum biochemical markers of trisomy 21 across the first and second trimester of pregnancy. Ann Clin Biochem. 2002; 39: 567-76.
24. Torring N,. Performance of first-trimester screening between gestational weeks 7 and 13. Clin Chem. 2009; 55: 1564-7.
25. Liao AW, Heath V, Kametas N, Spencer K, Nicolaides KH,. First-trimester screening for trisomy 21 in singleton pregnancies achieved by assisted reproduction. Hum Reprod. 2001; 16: 1501-4.
26. Sebire NJ, Snijders RJ, Hughes K, Sepulveda W, Nicolaides KH,. Screening for trisomy 21 in twin pregnancies by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation. Br J Obstet Gynaecol. 1996; 103: 999-1003.
27. Sepulveda W, Wong AE, Casasbuenas A,. Nuchal translucency and nasal bone in first-trimester ultrasound screening for aneuploidy in multiple pregnancies. Ultrasound Obstet Gynecol. 2009; 33: 152-6.